Review of CAR-T cell therapy for pancreatic ductal adenocarcinoma reports no specific outcomes or safety data.
First CAR-T for Pancreatic Cancer Approved
This narrative review addresses the application of CAR-T cell therapy for pancreatic ductal adenocarcinoma. However, the source explicitly s…
For the first time, a new drug approved for pancreatic cancer uses immune cells to attack solid tumors instead of just blood cancers.
Phase 2 Study of BGB-16673 in B-Cell Malignancies: Safety and Dose Findings
Could This New Drug Offer Hope for Patients with Tough Blood Cancers?
This ongoing Phase 1/2 trial evaluates BGB-16673 in B-cell malignancies, focusing on safety and dose determination. Primary outcomes include…
Patients with tough B-cell blood cancers may find a new option in the drug BGB-16673, currently being tested to find the right safe dose and…